This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Biosimilar Pegfilgrastim (Merck)
Merck & Co., Inc.
Drug Names(s): MK-6302, INS-20, Neulasta (Pegfilgrastim) Biosimilar
Description: INS-20 is a chemically modified version of GCSF in which a water soluble polymer called polyethylene glycol is attached to the protein. The pegylated protein has a prolonged biological activity after it is injected into the patient. INS-20 is a follow-on biologic to the FDA approved drug Neulasta.
Deal Structure: On February 12, 2009, Insmed announced that it has entered into a definitive agreement with Merck, whereby Merck, through an affiliate, will purchase all assets related to Insmed's follow-on biologics platform. These assets include INS-19 and INS-20. Under the terms of the agreement, Insmed will receive a total of $130 million for the assets. The acquisition was completed in March 2009.
Biosimilar Pegfilgrastim (Merck) News
Pink Sheet Fulphila Clinical Development Timeline
Additional information available to subscribers only: